What is Evolugate?
Based in Gainesville, Florida, Evolugate specializes in enhancing bio-industrial efficiency through its sophisticated platform focused on evolutionary strain optimization. The company operates at the intersection of advanced biological engineering and industrial productivity, providing innovative solutions that address complex challenges in manufacturing and pharmaceutical development. With a proven track record in scientific research, including high-impact initiatives related to COVID-19 and vaccine development, Evolugate serves a diverse clientele seeking to optimize biological processes for maximum output. Its unique methodology allows for the rapid adaptation of microbial strains, offering a distinct competitive advantage in an industry increasingly reliant on precision biotechnology.
How much funding has Evolugate raised?
Evolugate has raised a total of $116K across 1 funding round:
Debt
$116K
Debt (2021): $116K with participation from PPP
Key Investors in Evolugate
PPP
Public-Private Partnership
What's next for Evolugate?
With this late-stage funding secured, Evolugate is poised to scale its operations and expand its market reach. The strategic allocation of this capital will likely focus on deepening its R&D capabilities and broadening the application of its evolutionary strain technology across new industrial verticals. As the global demand for efficient, scalable bio-manufacturing solutions continues to rise, Evolugate is strategically positioned to capitalize on these trends. Future growth will likely involve strengthening partnerships within the pharmaceutical and industrial sectors, further cementing its reputation as a leader in bio-industrial innovation and operational excellence.
See full Evolugate company page
